Chaitra Jayadev

Chair(s): Patricia Udaondo (United States); Baruch Kuppermann (United States);

Recent lessons from the DRCR network trials
Jennifer Sun (United States)
Is OCT-A essential in diabetic eye management
Baruch Kuppermann (United States)
Vitreoretinal interface in diabetes: new perspectives
Stratos Gotzaridis (Greece)
The Management of DME and PDR in 2019
Chaitra Jayadev (United Kingdom/Italy)
Cases
Patricia Udaondo (United States)
Non-coding RNAs and epigenetics - potential future treatment for diabetic
Subrata Chakrabarti (Canada)

Topic: Medical Retina

Chair(s): Parikshit Gogate (India); Suzanne Gilbert (United States);

Opening
Parikshit Gogate (India); Suzanne Gilbert (United States)
Should we actively screen for glaucoma: Yes we must
Nathan Congdon (United Kingdom)
Should we actively screen for glaucoma: No it's foolish
Vijaya Lingam (India)
Medical management Vs Intervention: Medical management safe & easily available
S.R. Krishnadas (India)
SLT or trabeculectomy should be done before medications
David Friedman (United States)
Should we actively screen for diabetic retinopathy? - Yes we must
Rajiv Khandekar (Saudi Arabia)
Should we actively screen for diabetic retinopathy? - No its too expensiveand unnecessary
Van C. Lansingh (Mexico)
Early vs late laser for diabetic retinopathy or Anti-VEGFs for retinopathy? - Laser
Kolawole Ogundimu (Nigeria)
Early vs late laser for diabetic retinopathy or Anti-VEGFs for retinopathy? - Anti-VEGFs
Chaitra Jayadev (United Kingdom/Italy)

Topic: Ophthalmic Epidemiology